Integrated BioPharma (INBP) stock price, revenue, and financials

Integrated BioPharma market cap is $13 m, and annual revenue was $49.98 m in FY 2019

$13 M

INBP Mkt cap, 16-Sept-2020

$13.6 M

Integrated BioPharma Revenue Q3, 2020
Integrated BioPharma Gross profit (Q3, 2020)1.9 M
Integrated BioPharma Gross profit margin (Q3, 2020), %13.6%
Integrated BioPharma Net income (Q3, 2020)936 K
Integrated BioPharma EBIT (Q3, 2020)960 K
Integrated BioPharma Cash, 31-Mar-2020565 K
Integrated BioPharma EV21.6 M

Integrated BioPharma Revenue

Integrated BioPharma revenue was $49.98 m in FY, 2019

Embed Graph

Integrated BioPharma Income Statement

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

36.6m33.6m33.7m37.5m42.2m47.0m43.7m50.0m

Revenue growth, %

11%13%

Cost of goods sold

29.0m28.1m28.8m33.1m36.7m40.3m38.7m43.8m

Gross profit

7.6m5.5m4.9m4.4m5.5m6.7m5.0m6.2m

Gross profit Margin, %

21%16%14%12%13%14%11%12%

Sales and marketing expense

1.6m278.0k6.0k

General and administrative expense

8.1m4.4m3.5m3.5m3.4m3.5m3.3m3.5m

Operating expense total

8.1m4.4m3.5m3.5m3.4m3.5m3.3m3.5m

EBIT

(506.0k)1.1m1.4m933.0k2.1m3.2m1.7m2.7m

EBIT margin, %

(1%)3%4%2%5%7%4%5%

Interest expense

1.1m979.0k964.0k979.0k953.0k1.3m689.0k662.0k

Interest income

1.0k

Pre tax profit

(2.7m)110.0k220.0k869.0k1.2m1.9m1.0m2.0m

Income tax expense

11.0k17.0k(490.0k)326.0k354.0k

Net Income

(2.7m)93.0k131.0k735.0k958.0k2.3m679.0k1.7m

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

8.0m7.2m7.9m8.5m7.4m8.2m9.2m8.8m7.5m8.6m10.3m9.7m9.4m10.4m11.0m12.7m12.4m10.7m9.8m10.8m10.6m10.3m12.0m14.1m11.4m14.2m13.6m

Cost of goods sold

6.6m6.0m6.5m6.9m6.3m6.9m7.3m6.8m7.3m9.0m8.8m8.1m9.4m9.6m10.5m10.9m9.3m8.8m9.8m9.1m9.1m10.7m12.0m10.0m12.2m11.8m

Gross profit

1.4m1.2m1.3m1.6m1.1m1.2m1.5m727.0k1.3m1.3m899.0k1.3m975.0k1.3m2.2m1.5m1.3m1.0m1.0m1.5m1.2m1.3m2.1m1.4m2.0m1.9m

Gross profit Margin, %

18%17%17%18%15%15%17%10%15%12%9%14%9%12%17%12%13%10%10%14%12%11%15%12%14%14%

General and administrative expense

689.0k742.0k1.8m1.2m1.1m1.1m850.0k923.0k852.0k856.0k887.0k830.0k807.0k874.0k793.0k900.0k910.0k794.0k850.0k809.0k814.0k843.0k856.0k923.0k821.0k892.0k

Operating expense total

689.0k742.0k1.8m1.2m1.1m1.1m850.0k923.0k852.0k857.0k887.0k830.0k807.0k874.0k793.0k900.0k910.0k794.0k850.0k809.0k814.0k843.0k856.0k923.0k821.0k892.0k

Depreciation and amortization

65.0k

EBIT

740.0k507.0k(428.0k)369.0k31.0k165.0k619.0k(196.0k)449.0k399.0k12.0k485.0k168.0k450.0k1.4m570.0k429.0k211.0k198.0k660.0k405.0k487.0k1.2m476.0k1.2m960.0k

EBIT margin, %

9%7%(5%)4%0%2%7%(3%)5%4%0%5%2%4%11%5%4%2%2%6%4%4%9%4%8%7%

Interest expense

172.0k286.0k248.0k239.0k248.0k161.0k227.0k17.0k215.0k216.0k211.0k363.0k584.0k576.0k123.0k434.0k208.0k169.0k191.0k183.0k171.0k127.0k134.0k

Interest income

3.0k116.0k

Pre tax profit

595.0k(657.0k)(719.0k)(970.0k)828.0k(527.0k)458.0k(423.0k)432.0k614.0k(82.0k)269.0k(43.0k)87.0k775.0k(6.0k)306.0k(223.0k)(10.0k)491.0k214.0k304.0k1.1m349.0k1.1m1.0m

Income tax expense

29.0k67.0k24.0k28.0k20.0k54.0k126.0k71.0k68.0k(44.0k)338.0k103.0k55.0k58.0k143.0k37.0k112.0k67.0k

Net Income

363.0k(784.0k)(738.0k)(972.0k)817.0k(532.0k)298.0k397.0k(450.0k)403.0k547.0k(106.0k)241.0k(63.0k)33.0k649.0k(77.0k)238.0k(179.0k)(348.0k)388.0k159.0k246.0k923.0k312.0k959.0k936.0k

Integrated BioPharma Balance Sheet

Annual

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

563.0k388.0k649.0k216.0k124.0k285.0k480.0k135.0k184.0k294.0k48.0k354.0k84.0k60.0k450.0k92.0k66.0k196.0k284.0k54.0k62.0k365.0k45.0k431.0k525.0k67.0k565.0k

Accounts Receivable

2.0m1.3m1.4m2.3m3.0m1.9m2.0m2.3m1.9m2.3m3.4m2.8m2.8m4.0m3.6m3.8m4.4m2.7m2.7m4.6m3.2m3.4m4.5m5.0m3.4m4.9m4.3m

Prepaid Expenses

163.0k220.0k454.0k439.0k332.0k344.0k342.0k331.0k370.0k389.0k402.0k433.0k358.0k368.0k315.0k266.0k273.0k353.0k636.0k505.0k479.0k387.0k443.0k413.0k312.0k301.0k

Inventories

4.5m3.8m4.7m5.5m6.5m6.7m6.5m5.8m4.7m7.0m6.8m5.9m6.1m7.0m6.8m8.1m7.8m7.9m7.0m8.1m8.6m9.6m11.5m10.5m9.9m9.3m10.1m

Current Assets

11.7m9.9m8.0m9.2m10.7m9.9m10.0m9.2m7.8m10.5m11.1m10.0m9.8m11.9m11.7m12.7m13.1m11.6m10.6m13.2m12.3m13.7m16.5m16.4m14.1m14.5m15.3m

PP&E

1.5m1.4m1.5m1.4m1.3m1.3m1.2m1.2m1.2m1.5m1.5m1.4m1.4m1.5m1.5m1.5m1.5m1.7m1.6m1.7m1.7m1.6m1.8m1.8m1.7m1.7m1.7m

Total Assets

13.4m11.5m10.8m12.2m13.6m12.7m12.6m11.8m10.3m13.1m13.7m12.4m12.1m14.2m14.1m14.6m15.0m13.6m13.4m15.6m14.6m19.7m22.6m22.2m19.6m20.0m20.6m

Accounts Payable

4.6m3.4m4.8m6.4m7.0m6.5m5.6m5.0m4.9m6.4m5.9m5.8m6.0m6.5m6.1m4.8m5.6m4.7m3.7m5.6m4.9m6.0m7.2m6.0m5.1m4.3m6.1m

Short-term debt

7.8m7.8m7.8m1.5m875.0k908.0k5.2m4.8m4.0m5.3m6.2m5.2m4.9m6.7m5.0m5.8m5.0m4.7m4.9m5.7m5.2m5.6m7.2m7.2m5.9m6.3m5.1m

Current Liabilities

20.7m19.6m19.6m12.5m13.2m12.8m12.1m11.1m10.2m12.9m13.4m12.5m12.1m14.4m12.3m11.8m12.0m10.5m9.9m12.5m11.3m12.6m15.5m14.4m12.5m12.3m12.4m

Long-term debt

4.6m5.1m5.0m9.1m8.9m7.9m9.0m9.7m8.5m8.0m9.8m9.8m9.8m4.7m4.6m3.8m3.9m3.7m7.0m6.6m6.4m4.9m4.5m4.1m

Total Debt

7.8m7.8m7.8m6.1m6.0m5.9m869.0k598.0k596.0k754.0k15.9m13.7m707.0k713.0k824.0k959.0k946.0k1.0m8.7m9.5m8.9m12.5m13.8m13.6m10.7m10.8m9.2m

Total Liabilities

23.5m24.1m23.8m22.6m21.4m20.4m22.9m22.9m21.7m21.1m23.3m23.2m22.3m22.7m21.1m19.5m22.1m20.7m19.5m22.1m20.8m17.4m16.8m16.5m

Common Stock

42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k42.0k59.0k59.0k59.0k59.0k59.0k59.0k

Additional Paid-in Capital

44.6m44.6m44.6m44.6m44.6m44.6m44.6m44.6m44.6m44.6m44.6m44.6m44.7m44.7m44.7m44.7m44.7m44.7m44.8m44.8m44.8m50.0m50.1m50.1m50.2m50.2m50.2m

Retained Earnings

(51.8m)(52.6m)(53.3m)(55.9m)(55.0m)(55.6m)(54.5m)(54.1m)(54.6m)(54.3m)(53.7m)(53.8m)(53.7m)(53.8m)(53.7m)(52.3m)(52.4m)(52.2m)(50.8m)(51.2m)(50.8m)(49.8m)(49.5m)(48.6m)(48.0m)(47.0m)(46.1m)

Total Equity

(7.3m)(8.1m)(8.8m)(11.4m)(10.5m)(11.1m)(10.0m)(9.6m)(10.0m)(9.8m)(9.2m)(9.3m)(9.1m)(9.1m)(9.1m)(7.7m)(7.7m)(7.5m)(6.1m)(6.4m)(6.1m)195.0k466.0k1.4m2.2m3.2m4.1m

Debt to Equity Ratio

-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x-0.1 x

Debt to Assets Ratio

0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x0.1 x

Financial Leverage

-1.8 x-1.4 x-1.2 x-1.1 x-1.3 x-1.1 x-1.3 x-1.2 x-1 x-1.3 x-1.5 x-1.3 x-1.3 x-1.6 x-1.6 x-1.9 x-1.9 x-1.8 x-2.2 x-2.4 x-2.4 x101.1 x48.4 x16 x8.8 x6.3 x5 x

Integrated BioPharma Cash Flow

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

363.0k(422.0k)(1.2m)(972.0k)(155.0k)(687.0k)298.0k695.0k245.0k403.0k950.0k845.0k241.0k178.0k211.0k649.0k572.0k810.0k(179.0k)(527.0k)(139.0k)159.0k405.0k1.3m312.0k1.3m2.2m

Depreciation and Amortization

90.0k180.0k376.0k107.0k213.0k318.0k103.0k407.0k297.0k95.0k268.0k304.0k91.0k226.0k260.0k97.0k202.0k298.0k100.0k314.0k264.0k91.0k298.0k234.0k91.0k160.0k239.0k

Accounts Receivable

755.0k(125.0k)(31.0k)221.0k923.0k(176.0k)(441.0k)130.0k479.0k(119.0k)(1.2m)(608.0k)(165.0k)(1.4m)(995.0k)(630.0k)(1.3m)429.0k1.3m(575.0k)822.0k415.0k(721.0k)(1.2m)1.1m(441.0k)166.0k

Inventories

(858.0k)1.5m(2.7m)161.0k1.2m1.5m94.0k631.0k1.8m(1.3m)(1.1m)(189.0k)(309.0k)(1.2m)(1.1m)(324.0k)(70.0k)(124.0k)603.0k(413.0k)(910.0k)(1.9m)(3.8m)(2.8m)(1.1m)(471.0k)(1.2m)

Accounts Payable

(625.0k)(1.8m)(2.7m)(73.0k)547.0k39.0k(258.0k)(834.0k)(977.0k)763.0k310.0k193.0k887.0k1.4m908.0k(640.0k)166.0k(792.0k)(455.0k)1.4m697.0k1.9m3.0m1.9m1.3m403.0k2.3m

Cash From Operating Activities

217.0k(256.0k)14.0k(126.0k)(979.0k)(858.0k)769.0k1.0m2.1m(495.0k)(1.5m)44.0k436.0k(1.2m)(817.0k)(526.0k)547.0k1.2m1.6m640.0k1.3m593.0k(914.0k)(299.0k)1.7m1.1m3.5m

Purchases of PP&E

(1.0k)(7.0k)(82.0k)(8.0k)(8.0k)(21.0k)(2.0k)(29.0k)(115.0k)(168.0k)(188.0k)(227.0k)(41.0k)(40.0k)(40.0k)(41.0k)(83.0k)(310.0k)(107.0k)(210.0k)(216.0k)(18.0k)(287.0k)(350.0k)(58.0k)(101.0k)(158.0k)

Cash From Investing Activities

1.0k(2.0k)(70.0k)10.0k10.0k(3.0k)(2.0k)(29.0k)(115.0k)(168.0k)(188.0k)(227.0k)(41.0k)(38.0k)(38.0k)(41.0k)(83.0k)(310.0k)(107.0k)(206.0k)(210.0k)(26.0k)(294.0k)(358.0k)(58.0k)(98.0k)(70.0k)

Short-term Borrowings

(8.2m)(15.9m)(24.0m)(9.2m)(18.4m)(26.0m)(8.5m)(17.8m)(27.8m)(8.9m)(17.8m)(30.3m)(12.3m)(23.8m)(35.6m)(11.3m)(20.2m)(31.3m)(10.6m)(21.8m)(34.8m)(12.6m)(25.1m)(38.4m)

Long-term Borrowings

(11.0k)(20.0k)(20.0k)(3.0k)(8.0k)(18.0k)(32.0k)(24.0k)(67.0k)(108.0k)(35.0k)(64.0k)(88.0k)(39.0k)(72.0k)(101.0k)(30.0k)(100.0k)(175.0k)(50.0k)(101.0k)(174.0k)(60.0k)(115.0k)(157.0k)

Cash From Financing Activities

(11.0k)(20.0k)(20.0k)187.0k948.0k1.0m(342.0k)(891.0k)(1.9m)506.0k1.3m86.0k(382.0k)1.2m1.2m264.0k(793.0k)(1.1m)(1.3m)(512.0k)(1.2m)(430.0k)1.0m860.0k(1.6m)(1.4m)(3.4m)

Net Change in Cash

207.0k(278.0k)(76.0k)71.0k(21.0k)140.0k425.0k80.0k129.0k(157.0k)(403.0k)(97.0k)13.0k(11.0k)379.0k(303.0k)(329.0k)(199.0k)152.0k(78.0k)(70.0k)137.0k(183.0k)203.0k50.0k(408.0k)90.0k

Interest Paid

772.0k126.0k298.0k486.0k183.0k361.0k537.0k174.0k351.0k539.0k173.0k344.0k535.0k195.0k472.0k676.0k198.0k394.0k596.0k201.0k369.0k568.0k123.0k228.0k323.0k

Income Taxes Paid

(26.0k)(44.0k)(2.0k)(13.0k)(18.0k)5.0k7.0k45.0k46.0k54.0k72.0k117.0k227.0k294.0k109.0k130.0k2.0k123.0k193.0k155.0k303.0k

Integrated BioPharma Ratios

USDQ1, 2012

Financial Leverage

-1.8 x